Details werden geladen...
Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes | The Manila Times
The OPTI-2 trial provides early clinical evidence that liver-targeted mealtime insulin may help decouple tight glucose control from hypoglycemia risk, a longstanding tradeoff in intensive insulin therapy that has persisted despite advances in monitoring and delivery technologies
Ähnliche Seiten
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026/2357329Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma | The Manila Times
https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma/2355202New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 | The Manila Times
https://www.manilatimes.net/2026/06/09/tmt-newswire/globenewswire/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-under-alloimmune-pressure-and-scalable-manufacturing-at-ada-2026/2361164Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/madrigal-presents-data-demonstrating-rezdiffra-reduced-markers-of-cardiovascular-and-liver-related-risk-in-patients-with-mash/2352596iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity/2356645